All Stories

  1. Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

    Article • Diabetes Care, February 2021, American Diabetes Association

    Geremia Bolli

  2. Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

    Article • Diabetes Care, September 2020, American Diabetes Association

    Geremia Bolli

  3. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

    Article • Postgraduate Medicine, February 2019, Taylor & Francis

    Geremia Bolli, Dr Marcus Hompesch

  4. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

    Article • Diabetes Care, October 2018, American Diabetes Association

    Geremia Bolli

  5. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen

    Article • Diabetes Obesity and Metabolism, October 2018, Wiley

    Geremia Bolli

  6. John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

    Article • Diabetes Care, September 2018, American Diabetes Association

    Geremia Bolli

  7. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus

    Article • Diabetes Obesity and Metabolism, July 2018, Wiley

    Geremia Bolli

  8. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use

    Article • Diabetes Obesity and Metabolism, July 2018, Wiley

    Geremia Bolli

  9. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)

    Article • Diabetes Obesity and Metabolism, August 2017, Wiley

    Geremia Bolli

  10. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

    Article • Diabetes Obesity and Metabolism, July 2017, Wiley

    Professor Alexandra Kautzky-Willer, Geremia Bolli

  11. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)

    Article • Diabetes Obesity and Metabolism, February 2015, Wiley

    Geremia Bolli

  12. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)

    Article • Diabetic Medicine, October 2013, Wiley

    Geremia Bolli